Teprotumumab for the treatment of chronic thyroid eye disease

BACKGROUND: Teprotumumab, a novel IGF-1R antibody was recently shown to significantly reduce the signs of active Thyroid eye disease (TED). The current study reviews its efficacy in chronic TED. METHODS: In this retrospective review, consecutive patients with chronic stable TED (>2 years), who ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Ugradar, Shoaib, Kang, Julia, Kossler, Andrea L., Zimmerman, Erin, Braun, Jenna, Harrison, Andrew R., Bose, Swaraj, Cockerham, Kimberly, Douglas, Raymond S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307784/
https://www.ncbi.nlm.nih.gov/pubmed/34244669
http://dx.doi.org/10.1038/s41433-021-01593-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307784/
https://www.ncbi.nlm.nih.gov/pubmed/34244669
http://dx.doi.org/10.1038/s41433-021-01593-z

Ejemplares similares